{"id":"W4403539151","doi":"10.1158/1078-0432.ccr-24-1562","title":"Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma","year":2024,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Foundation Medicine; European Society for Medical Oncology; PharmaMar; Les Laboratories Pierre Fabre; AstraZeneca; Amgen; Pfizer; Astellas Pharma; F. Hoffmann-La Roche","keywords":"Cetuximab; Medicine; Pharmacodynamics; Internal medicine; Head and neck squamous-cell carcinoma; Tolerability; Oncology; Pharmacokinetics; Phases of clinical research; Adverse effect; Gastroenterology; Response Evaluation Criteria in Solid Tumors; Head and neck cancer; Clinical trial; Colorectal cancer; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001157824,0.000120843,0.0003999578,0.0003289069,0.00005894868,0.00003156786,0.0001196957,0.00007534041,0.000094635],"category_scores_gemma":[0.0001691083,0.00007035267,0.00005348306,0.001403726,0.0002950255,0.00007875825,0.0001026887,0.0009458335,0.000003965512],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001752961,"about_ca_system_score_gemma":0.000343427,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002087406,"about_ca_topic_score_gemma":0.003421256,"domain_scores_codex":[0.9975749,0.0003805146,0.0005334054,0.0004118326,0.0008196041,0.0002797812],"domain_scores_gemma":[0.9987727,0.0003988208,0.00006188936,0.0003577451,0.0002988149,0.0001100114],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004133882,0.01211324,0.9769384,0.0002275112,0.00003084661,0.0001026666,0.0007076141,0.00001343649,0.0001282538,0.0000103764,0.0001954065,0.005398402],"study_design_scores_gemma":[0.04969834,0.01285406,0.934142,0.0007913374,0.00005440847,0.000001202757,0.0007464171,0.00100503,0.0004519011,0.00002275984,0.0001342767,0.00009826758],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9972202,0.0003478721,0.000001641843,0.001042689,0.00002275539,0.001019513,0.00002115667,0.00001069205,0.00031344],"genre_scores_gemma":[0.9994116,0.00002425728,0.000007718279,0.00009370124,0.00003635918,0.00008650633,0.00001895576,0.00002085146,0.0002999997],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04556445,"threshold_uncertainty_score":0.4109229,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08702096082543363,"score_gpt":0.454809325563476,"score_spread":0.3677883647380423,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}